2Seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off most of its research and lost nearly all of its market value.
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off most of its research and lost nearly all of its market value.
